This free survey is powered by
  1. Surveys
  2. 2014
  3. February
  4. D
  5. DRG Questionnaire
0%
Exit Survey
 
 
Dear Valued Customer,

We would like to thank you for purchasing DRG TM-CA 72.4 (EIA-5071) immunoassays. In our continuing effort to improve our products and customer support we are conducting a survey to better understand how TM-CA 72.4 is being utilized worldwide. We understand that your time is valuable; therefore we would greatly appreciate your cooperation in answering the following questions:


Thank you very much for your time and support. Please start with the survey now by clicking on the Continue button below.
 
 
 
What type of cancer do you primarily test with TM-CA 72.4?
 
Stomach
 
Ovarian
 
Pancreatic
 
Liver
 
Gall
 
Colon
 
Mammary
 
Cervical
 
Endometrium
 
Other (please specify)
 
 
 
Have you tested other types of cancer with TM-CA 72.4?
 
Stomach
 
Ovarian
 
Pancreatic
 
Liver
 
Gall
 
Colon
 
Mammary
 
Cervical
 
Endometrium
 
Other (please specify)
 

 
 
 
Stomach
   
Ovarian
   
Pancreatic
   
Liver
   
Gall
   
Colon
   
Mammary
   
Cervical
   
Endometrium
   
Other
   
 
 
 
Which is your most frequent application for TM-CA 72.4?
 
Screening
 
Diagnosis
 
Prognosis
 
Therapy Monitoring
 
 
 
Does TM-CA 72.4 correlate positively or negatively with therapeutic treatment?
 
Yes
 
No
 
 
 
Have you tested TM-CA 72.4 with other known tumor markers?
If yes, please indicate which ones.
 
Yes
 
No
 
 
 
 
How many patients have you evaluated?
   
 
 
 
Would you be willing to collaborate with DRG in conducting clinical studies using TM-CA 72.4?